151 related articles for article (PubMed ID: 22789039)
1. Pharmaceutical companies vs. the State: who is responsible for post-trial provision of drugs in Brazil?
Wang DW; Ferraz OL
J Law Med Ethics; 2012; 40(2):188-96. PubMed ID: 22789039
[TBL] [Abstract][Full Text] [Related]
2. Conflicts of interest in research involving human beings.
Greco D; Diniz NM
J Int Bioethique; 2008; 19(1-2):143-54, 202-3. PubMed ID: 18664007
[TBL] [Abstract][Full Text] [Related]
3. [Essential drugs and pharmaceutical care: reflection on the access to drugs through lawsuits in Brazil].
Sant'ana JM; Pepe VL; Osorio-de-Castro CG; Ventura M
Rev Panam Salud Publica; 2011 Feb; 29(2):138-44. PubMed ID: 21437372
[TBL] [Abstract][Full Text] [Related]
4. Why are generic drugs being held up in transit? Intellectual property rights, international trade, and the right to health in Brazil and beyond.
Rosina MS; Shaver L
J Law Med Ethics; 2012; 40(2):197-205. PubMed ID: 22789040
[TBL] [Abstract][Full Text] [Related]
5. Human rights responsibilities of pharmaceutical companies in relation to access to medicines.
Lee JY; Hunt P
J Law Med Ethics; 2012; 40(2):220-33. PubMed ID: 22789042
[TBL] [Abstract][Full Text] [Related]
6. Access to life-saving medicines and intellectual property rights: an ethical assessment.
Schroeder D; Singer P
Camb Q Healthc Ethics; 2011 Apr; 20(2):279-89. PubMed ID: 21435303
[No Abstract] [Full Text] [Related]
7. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
Rosenberg ST
Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceutical companies and global lack of access to medicines: strengthening accountability under the right to health.
Grover A; Citro B; Mankad M; Lander F
J Law Med Ethics; 2012; 40(2):234-50. PubMed ID: 22789043
[TBL] [Abstract][Full Text] [Related]
9. Challenges of access to medicine and the responsibility of pharmaceutical companies: a legal perspective.
Ahmadiani S; Nikfar S
Daru; 2016 May; 24(1):13. PubMed ID: 27141958
[TBL] [Abstract][Full Text] [Related]
10. [The right to health. Constitutional dimensions].
Pestalozza C
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 Sep; 50(9):1113-8. PubMed ID: 17828472
[TBL] [Abstract][Full Text] [Related]
11. Judicialisation of the right to health in Brazil.
Biehl J; Petryna A; Gertner A; Amon JJ; Picon PD
Lancet; 2009 Jun; 373(9682):2182-4. PubMed ID: 19560587
[No Abstract] [Full Text] [Related]
12. [Legal and sanitary aspects conditioning access to medicines in Brazilian courts].
Pandolfo M; Delduque MC; Amaral RG
Rev Salud Publica (Bogota); 2012; 14(2):340-9. PubMed ID: 23250376
[TBL] [Abstract][Full Text] [Related]
13. Rights to specialized health care in Norway: a normative perspective.
Norheim OF
J Law Med Ethics; 2005; 33(4):641-9. PubMed ID: 16686235
[No Abstract] [Full Text] [Related]
14. Patients' rights and access to unconventional treatment.
Gillett G
N Z Med J; 2005 May; 118(1215):U1458. PubMed ID: 15915182
[No Abstract] [Full Text] [Related]
15. Informed consent: Enforcing pharmaceutical companies' obligations abroad.
Lee SB
Health Hum Rights; 2010 Jun; 12(1):15-28. PubMed ID: 20930251
[TBL] [Abstract][Full Text] [Related]
16. Post-trial access to study medication: a Brazilian e-survey with major stakeholders in clinical research.
Dainesi SM; Goldbaum M
J Med Ethics; 2012 Dec; 38(12):757-62. PubMed ID: 22915826
[TBL] [Abstract][Full Text] [Related]
17. [Legal decisions on access to medicines in Pernambuco, Northeastern Brazil].
Stamford A; Cavalcanti M
Rev Saude Publica; 2012 Oct; 46(5):791-9. PubMed ID: 23128255
[TBL] [Abstract][Full Text] [Related]
18. [Pharmaceutical patents and public health: challenges for the Brazilian antiretroviral treatment policy].
Meiners CM
Cad Saude Publica; 2008 Jul; 24(7):1467-78. PubMed ID: 18670671
[TBL] [Abstract][Full Text] [Related]
19. Committees for Ethics in Research involving human subjects.
Hossne WS; Vieira S; De Freitas CB
J Int Bioethique; 2008; 19(1-2):131-41, 200. PubMed ID: 18664006
[TBL] [Abstract][Full Text] [Related]
20. [Bioethical issues on the access to drugs in the practice of ophthalmology in Colombia].
Mazzanti-di Ruggiero MLÁ; Sarmiento-Dueñas ME; Hernández-Rincón EH; Martínez-Ceballos MA; Muñoz-Ortiz J
Medwave; 2019 Mar; 19(2):e7585. PubMed ID: 30897073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
